Transition Period Comparative Data (Details) - USD ($) |
3 Months Ended | 9 Months Ended | 11 Months Ended | 12 Months Ended | |||||
|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 |
Jun. 30, 2016 |
Sep. 30, 2015 |
Jun. 30, 2015 |
Mar. 31, 2016 |
Mar. 31, 2015 |
Jun. 30, 2016 |
Mar. 31, 2016 |
Jun. 30, 2015 |
|
| Expenses | |||||||||
| Research and development | $ 652,576 | $ 709,314 | $ 321,720 | $ 228,125 | $ 244,635 | $ 1,758,701 | $ 1,222,194 | $ 470,987 | |
| General and administrative | 1,263,243 | 968,734 | 761,323 | 625,917 | 339,214 | 2,935,299 | 2,647,800 | 920,031 | |
| Total expense | 1,915,819 | 1,678,048 | 1,083,043 | 854,042 | 583,849 | 4,694,000 | 3,869,994 | 1,391,018 | |
| Other income (expenses) | |||||||||
| Grant income | 20,500 | 29,999 | 137,500 | 254,834 | 264,333 | 167,499 | |||
| Interest income | 90 | 186 | 496 | 175 | 1,339 | 1,328 | 175 | ||
| Change in fair value of warrant derivative liability | (157,216) | (860,275) | 14,015 | 1,571 | (968,840) | (106,994) | 1,571 | ||
| Total other income (expenses) | (157,126) | (839,589) | 14,511 | 31,745 | 137,500 | (712,167) | 159,167 | 169,245 | |
| Net loss for the period | $ (2,072,945) | $ (2,517,637) | $ (1,068,532) | $ (822,297) | $ (2,888,530) | $ (446,349) | $ (5,406,167) | $ (3,710,827) | $ (1,221,773) |
| Loss per share - basic and diluted (in dollars per share) | $ (0.13) | $ (0.17) | $ (0.09) | $ (0.11) | $ (0.08) | $ (0.40) | $ (0.32) | $ (0.20) | |
| Weighted average number of shares outstanding - basic and diluted (in shares) | 15,701,709 | 15,111,088 | 12,392,115 | 7,823,683 | 5,493,200 | 13,349,482 | 11,702,313 | 6,240,780 | |
| Cash flow Data: | |||||||||
| Net cash used in operating activities | $ (1,067,119) | $ (1,100,342) | $ (796,245) | $ (576,492) | $ (433,065) | $ (3,312,969) | $ (2,789,118) | $ (980,044) | |
| Net cash used in investing activities | (34,017) | (47,215) | (118,830) | (23,378) | (99,197) | (203,667) | (179,830) | (111,727) | |
| Net cash provided by financing activities | 2,572,896 | 4,241,627 | 1,220,001 | 3,342,584 | 5,011,314 | 4,931,627 | |||
| Net increase in cash for the period | $ (1,101,136) | $ 1,425,339 | $ (915,075) | $ 3,641,757 | $ 687,739 | $ (174,052) | $ 2,042,366 | $ 3,839,856 | |
| X | ||||||||||
- Definition Income earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements. No definition available.
|
| X | ||||||||||
- Definition Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. No definition available.
|
| X | ||||||||||
- Definition Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). No definition available.
|